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A single nucleotide polymorphism within the PTPN22 gene is a strong genetic risk factor
predisposing to the development of multiple autoimmune diseases. PTPN22 regulates
Syk and Src family kinases downstream of immuno-receptors. Fungal β-glucan recep-
tor dectin-1 signals via Syk, and dectin-1 stimulation induces arthritis in mouse mod-
els. We investigated whether PTPN22 regulates dectin-1 dependent immune responses.
Bone marrow derived dendritic cells (BMDCs) generated from C57BL/6 wild type (WT) and
Ptpn22−/− mutant mice, were pulsed with OVA323-339 and the dectin-1 agonist curdlan
and co-cultured in vitro with OT-II T-cells or adoptively transferred into OT-II mice, and
T-cell responses were determined by immunoassay. Dectin-1 activated Ptpn22−/− BMDCs
enhanced T-cell secretion of IL-17 in vitro and in vivo in an IL-1β dependent manner.
Immunoblotting revealed that compared to WT, dectin-1 activated Ptpn22−/− BMDCs dis-
played enhanced Syk and Erk phosphorylation. Dectin-1 activation of BMDCs expressing
Ptpn22R619W (the mouse orthologue of human PTPN22R620W) also resulted in increased
IL-1β secretion and T-cell dependent IL-17 responses, indicating that in the context of
dectin-1 Ptpn22R619W operates as a loss-of-function variant. These findings highlight
PTPN22 as a novel regulator of dectin-1 signals, providing a link between genetically
conferred perturbations of innate receptor signaling and the risk of autoimmune disease.
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 Additional supporting information may be found in the online version of this article at thepublisher’s web-site
Introduction
The nonsynonymous PTPN22 polymorphism C1858T (encoding
R620W) is a strong risk factor for the development of multiple
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autoimmune diseases, including rheumatoid arthritis (RA), type I
diabetes, lupus and juvenile idiopathic arthritis (JIA) [1]. PTPN22
encodes a tyrosine phosphatase that negatively regulates Src and
Syk family kinase (SFK) activity downstream of the T-cell antigen
receptor (TCR) [2]. Notably, T-cells from Ptpn22−/− mice exhibit
enhanced TCR signaling resulting in homeostatic expansion of
CD4+effector cells [3]. It has become clear that PTPN22 regu-
lates many pathways in different cell types including the B-cell
C© 2017 The Authors. European Journal of Immunology published by WILEY-VCH Verlag GmbH & Co.
KGaA, Weinheim.
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receptor [4], the αLβ2 integrin LFA-1 [5] and Toll-Like Recep-
tor (TLR) signaling pathways [6–9]. While it has become widely
accepted that the autoimmune associated PTPN22R620W variant
displays reduced binding to the tyrosine kinase Csk, due to a mis-
sensemutation in the P1 domain, [2, 10] precisely how the R620W
variant affects PTPN22 function is more complex. Both gain- and
loss-of-phosphatase function effects have been reported, depend-
ing on the cellular context and signaling pathway under investi-
gation [5, 9–11].
Antigen presenting cells (APCs) are critical for sensing and
mediating effective clearance of pathogens. Ptpn22 is highly
expressed in myeloid cells and a functional role for Ptpn22 in reg-
ulating TLR signaling pathways in dendritic cells (DC) has been
established [9, 12]. For example, Ptpn22 negatively regulates LPS-
induced TLR4 signaling resulting in enhanced IL-12p40 secretion
and T-cell proliferation [9], while TLR3, TLR4 and TLR7 induced
type 1 interferon production are positively regulated by the phos-
phatase through direct binding to TRAF3 leading to TRAF3 ubiqui-
tination and degradation [6, 8]. Other studies have demonstrated
regulation of inducible phosphorylation of NLRP3, a component of
the inflammasome, by Ptpn22 [13]. These data raise the possibility
that Ptpn22 plays amore fundamental role in APC function and the
regulation of adaptive immunity than was hitherto appreciated.
C-type lectin receptor dectin-1 binds β-1,3-glucan, a compo-
nent of fungal, bacterial and plant cell walls [14]. Dectin-1 engage-
ment regulates antigen uptake, pathogen sensing and inflamma-
tory responses, and promotes DC maturation, a process marked by
enhanced expression of cell surface co-stimulatory molecules and
secretion of IL-1β, IL-6, IL-12 and TNFα [15, 16]. These functions
are mediated by activation of Syk, Erk, MAPK and NFκB [17].
Furthermore, dectin-1 induced DC maturation instructs CD4+
T-cell priming and differentiation into IL-17 producing T-helper
cells [18, 19]. IL-17 is essential for driving host defense to fungal
pathogens, mediating neutrophil recruitment and anti-microbial
peptide production [18]. At the same time, IL-17 has been impli-
cated as a key cytokine in inflammatory responses associated with
RA, JIA, and psoriasis [20].
Negative regulation of dectin-1 signaling is not well under-
stood. Given recent studies demonstrating that Ptpn22 regulates
multiple TLR responses in DCs, and that dectin-1 signaling utilizes
the Ptpn22 substrate Syk, we reasoned that Ptpn22 might regulate
dectin-1 signaling, controlling the capability of dectin-1 matured
BMDCs to promote adaptive immune responses.
Results
PTPN22 regulates IL-17 production induced by
curdlan activated BMDCs in vitro
We hypothesized that Ptpn22, a negative regulator of Syk, oper-
ates in DCs to negatively regulate dectin-1 signals, and that the
absence of Ptpn22 would potentiate DC dependent induction of
T-cell IL-17 responses. We first compared T-helper cell differen-
tiation after activation by WT or Ptpn22−/− BMDCs stimulated
with the β-1-3-glucan curdlan, a dectin-1 specific agonist. In vitro
WT and Ptpn22−/− BMDCs, generated in the presence of GM-CSF,
showed no differences in the proportion or number of CD11c+
BMDCs generated (Supporting Information Fig. 1A and B). Imma-
ture BMDCs were pulsed overnight with OVA323-339 peptide in the
presence or absence of curdlan, and co-cultured with CD4+ OT-II
T-cells. Supernatants were assessed for cytokine expression. As
early as day 3 of co-culture, curdlan stimulated Ptpn22−/− BMDCs
pulsed with OVA323-339 induced significantly more IL-17 produc-
tion by T-cells than WT BMDCs; no differences were observed
for IFNγ or TNFα (Fig. 1A). Increased levels of IL-17 induced
by Ptpn22−/− BMDCs were sustained until day 6 at which point
a significant decrease in IFNγ was documented, as compared to
WT BMDC:T-cell co-cultures (Fig. 1B). Secretion of TNFα was
increased by curdlan primed DC, but was not regulated by the
presence of PTPN22. This enhanced IL-17 phenotype was sus-
tained for up to 10 days, as determined by immunoassay (Sup-
porting Information Fig. 1C), and flow cytometry (Fig. 1C and D),
but the reduction in IFNγ secretion was lost by this time point.
Differences in T-cell proliferation or viability following co-culture
with WT or Ptpn22−/− BMDCs did not account for differences
in the IL-17 responses (Supporting Information Fig. 1D and E).
These data indicated that Ptpn22−/− BMDCs have an enhanced
capability to induce dectin-1 dependent IL-17 T-cell responses.
Curdlan activated Ptpn22−/− BMDCs potentiate IL-17
responses in vivo
To confirm this finding in vivo, WT or Ptpn22−/− BMDCs pulsed
overnight with OVA323-339 in the presence or absence of curd-
lan, were adoptively transferred into the left footpad of OT-II
mice. After 7 days, draining (left) and non-draining (right) lymph
nodes (LN) of recipient OT-II mice were harvested for analysis.
The number of draining or non-draining LN cells derived from
recipient OT-II mice was equal in mice that had received either
WT or Ptpn22−/− BMDCs (Fig. 2A, Supporting Information Fig.
2A). Levels of IL-17, IFNγ, and TNFα were undetectable follow-
ing stimulation of non-draining LN T-cells with anti-CD3 alone
(Supporting Information Fig. 2B). By comparison, stimulation of
draining LN T-cells revealed enhanced levels of IL-17, IFNγ, and
TNFα secretion in recipients of BMDCs pulsed with OVA323-339,
and were further enhanced by the BMDCs pulsed with OVA323-339
and curdlan (Fig. 2B). Once again, OVA323-339 and curdlan primed
Ptpn22−/− BMDCs induced significantly more IL-17 secretion from
draining LN than recipients of WT BMDCs (Fig. 2B), while no dif-
ferences in IFNγ or TNFα secretion were observed. These data
validated the in vitro findings in Fig. 1, further confirming that
PTPN22 regulates curdlan induced IL-17 responses in the context
of the OT-II TCR transgenic mouse model.
Ptpn22 regulates curdlan dependent IL-1β production
by BMDCs
Dectin-1 engagement on BMDCs leads to the production of pro-
inflammatory cytokines such as IL-1β, IL-6, IL-12/23p40 and
C© 2017 The Authors. European Journal of Immunology published by
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Figure 1. PTPN22 regulates T-cell dependent IL-17 responses induced by curdlan stimulated BMDCs in vitro. Wild type (WT) and Ptpn22−/− derived
bone marrow derived dendritic cells (BMDCs) were pulsed overnight with OVA323-339 in the presence or absence of curdlan and co-cultured with
OT-II T-cells. Cell-free supernatants were assessed for IL-17, IFNγ, and TNFα production by immunoassay on day 3 (A) and day 6 (B). Each point
represents independent WT (closed triangle) or Ptpn22−/− (open circle) BMDC preparations, connecting lines between WT and Ptpn22−/− BMDC
samples are paired by the same WT OT-II T-cell preparation. Data are of (A) 4 and (B) 7 independent experiments with one sample per group
per experiment. NS = not significant, *p < 0.05, **p < 0.01, ***p < 0.001 by two-way ANOVA, applying Sidak’s multiple comparisons test. (C and
D) T-cells co-cultured for 6 days with WT or Ptpn22−/− BMDCs were harvested and replated in IL-2 and IL-23 for a further 4 days. At day 10 cells
were restimulated for 6 h with PMA and ionomycin in the presence of monensin and intracellular expression of IL-17 and IFNγ determined by
flow cytometry. (C) One representative cytometric dot plot of 5 independent experiments. (D) Pooled data of 5 independent experiments with one
sample per group per experiment and represent mean + S.E.M. NS = not significant, **p < 0.01 by two-way ANOVA, applying Sidak’s multiple
comparisons test.
C© 2017 The Authors. European Journal of Immunology published by
WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.
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Figure 2. PTPN22 regulates T-cell dependent IL-17 responses induced by curdlan stimulated BMDCs in vivo. Wild type (WT) and Ptpn22−/− derived
bone marrow derived dendritic cells (BMDCs) were pulsed overnight with OVA323-339 in the presence or absence of curdlan. BMDCs were harvested
and injected into the left footpad of OT-II mice. Seven days post immunization draining popliteal lymph nodes were isolated and the number
of cells within the draining (A) lymph nodes determined by Trypan blue counting. Total draining (B) lymph node T-cells were stimulated with
immobilized anti-CD3 for 48 h and cell-free supernatant assayed for IL-17, IFNγ and TNFα by immunoassay. Data are representative of three
independent experiments with four mice per group per experiment, each data point representing an individual OT-II mouse lymph node. Bars
represent the mean ± S.D. NS = not significant, **p < 0.01, ***p < 0.001 by two-way ANOVA, applying Sidak’s multiple comparisons test.
TNFα, cytokines required for the differentiation of IL-17 produc-
ing T-cells [16]. We compared the cytokine profile of supernatants
from WT and Ptpn22−/− BMDCs stimulated in vitro with curdlan.
We observed no significant differences in IL-6, IL-12/23p40, or
TNFα production between WT and Ptpn22−/− BMDCs in response
to curdlan (Fig. 3A). However, a modest but significant increase
in the secretion of IL-1β by Ptpn22−/− BMDCs was detected over a
range of curdlan concentrations (Fig. 3A and Supporting Informa-
tion Fig. 3A), a finding that was reproduced when BMDCs were
stimulated with another dectin-1 agonist, heat-killed C. albicans
(HKCA) (Supporting Information Fig. 3B). Ptpn22 did not regulate
inflammatory cytokine production in response to TLR4 agonist LPS
(Supporting Information Fig. 3C). Secretion of IL-1β was dectin-1
dependent (Fig. 3B) and dectin-1 expression was similar between
WT and Ptpn22−/− BMDCs (Supporting Information Fig. 4A and
B) and was independent of changes in the numbers or proportions
of CD11c+ BMDCs, or to differences in cell viability (Support-
ing Information Fig. 1A, B and Supporting Information Fig. 4C).
Dectin-1 signaling also regulates DC maturation and phagocyto-
sis, but we were unable to detect differences between genotypes
(Supporting Information Fig. 4D and E). These data demonstrated
that Ptpn22 confers a highly selective role in regulating dectin-1
induced IL-1β secretion.
Inhibition of IL-1β abrogates Ptpn22−/− induced
enhancement in IL-17 secretion
IL-1β is a potent cytokine, whose secretion and activity is tightly
controlled such that even modest changes in IL-1β expression
may confer functional effects [21]. To determine whether differ-
ences in IL-1β secretion between WT and Ptpn22−/− BMDCs were
functionally relevant, BMDC:T-cell co-culture experiments were
repeated in the presence of IL-1 receptor antagonist (IL-1RA),
a natural ligand which binds to IL-1R and blocks IL-1β signal-
ing. In vitro curdlan activated BMDCs induced IL-17 responses
in an IL-1β dependent manner (Supporting Information Fig. 5A).
Furthermore, adoptive transfer of OVA323-339 and curdlan pulsed
Ptpn22−/− BMDCs into OT-II mice by footpad injection resulted in
significantly enhanced IL-17 secretion compared to WT BMDCs,
and addition of IL-1RA mediated a striking reduction in IL-17
expression, abrogating the difference between WT and Ptpn22−/−
BMDC induced IL-17 expression (Fig. 4, Supporting Information
Fig. 5B). In contrast to IL-17, IL-1RA mediated reductions in IFNγ
and TNFα were more modest. These data suggested that differ-
ences in IL-1β production between WT and Ptpn22−/− BMDCs are
sufficient to mediate functional changes in T-cell responses.
Ptpn22 regulates dectin-1 dependent Syk and Erk
activation in BMDCs
Syk activation is crucial for dectin-1 signaling, raising the
possibility that Ptpn22 negatively regulates dectin-1 induced
secretion of IL-1β via a Syk dependent mechanism. We con-
firmed previous experimental findings [22, 23] that curdlan
induced IL-1β secretion was Syk and Erk dependent (Support-
ing Information Fig. 6A–C) using specific Syk and Erk kinase
inhibitors. We next compared the kinetics of Syk phosphoryla-
tion in WT and Ptpn22−/− BMDCs in response to a dectin-1
agonist. For technical reasons, including high antibody back-
ground signals obtained by immunoblotting when cells were
stimulated with curdlan, we used HKCA, a potent stimulator
of IL-1β secretion and dectin-1 dependent Syk activation (Sup-
porting Information S3B + S6D). Dectin-1 induced Syk activa-
tion was enhanced and prolonged in Ptpn22−/− BMDCs when
compared toWT cells (Fig. 5A and B). Following receptor proximal
Syk activation, the dectin-1 signaling pathway diverges, leading
to activation of a number of signaling pathways including Erk1/2,
NFκB and p38 MAPK. We evaluated each of these pathways in
turn and observed that, unlike IκBα and p38, Erk phosphoryla-
tion was significantly enhanced in the absence of Ptpn22 follow-
ing dectin-1 stimulation (Supporting Information Fig. 6E, F and
Fig. 5A and C). Erk phosphorylation was also significantly
C© 2017 The Authors. European Journal of Immunology published by
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Figure 3. Ptpn22 regulates BMDC IL-1β secretion in response to curd-
lan. (A) WT and Ptpn22−/− derived bone marrow derived dendritic cells
(BMDCs) were stimulated for 24 h in the presence or absence of curd-
lan. Cell-free supernatants were assessed for IL-1β, IL-6, IL-12/23p40,
and TNFα by immunoassay. Data are pooled from 8 to 12 independent
experiments with one sample per group per experiment, and represent
mean ± S.D. NS = not significant, **p < 0.01, ***p < 0.001 applying two-
way ANOVA, with Sidak’s multiple comparisons test. (B) WT BMDCs
were incubated in the presence or absence of α-dectin-1 or IgG2a isotype
control antibody for 30 min prior to stimulation for 24 h in the pres-
ence or absence of curdlan. Cell-free supernatants were assessed for
IL-1β by immunoassay. Data are pooled from five independent experi-
ments with one sample per group per experiment, and represent mean
+ S.E.M. NS = not significant, *p < 0.05, **p < 0.01 applying one-way
ANOVA, with Holm-Sidak’s multiple comparisons test.
increased in curdlan stimulated Ptpn22−/− BMDCs when com-
pared to WT cells (Supporting Information Fig. 6G, H). Together
these data indicated that Ptpn22 negatively regulates dectin-1
induced Syk and Erk phosphorylation.
The autoimmune risk variant Ptpn22R619W promotes
curdlan dependent signaling and IL-17 production
Finally, we investigated whether the mouse orthologue of the
human autoimmune disease associated PTPN22R620W variant per-
turbs dectin-1 induced BMDC function. BMDCs from WT mice
and mice expressing Ptpn22R619W were pulsed with OVA323-339
peptide in the presence or absence of curdlan, and injected into
the left footpad of OT-II recipient mice. After 7 days, draining
and non-draining LN suspensions were prepared prior to stim-
ulation with immobilised anti-CD3, and assayed for IL-17, IFNγ
and TNFα. As with Ptpn22−/− BMDCs, we observed an increase
in the secretion of IL-17 from draining LN of mice that received
Ptpn22R619W BMDCs when compared to WT (Fig. 6A), accompa-
nied by enhanced IL-1β secretion (Fig. 6B). These data suggest that
in the context of dectin-1 signaling the disease-associated variant
confers reduced function leading to enhanced IL-1β secretion and
increased IL-17 responses by T-cells.
Discussion
We report that in BMDCs derived from both Ptpn22−/− and
Ptpn22R619W mice dectin-1 induced Syk and Erk signaling is
potentiated, leading to increased IL-1β secretion and IL-17 T-cell
responses. These data provide the first association between DC
anti-fungal dectin-1 signals and the phosphatase Ptpn22, provid-
ing evidence supporting a role for this phosphatase as a negative
regulator of this signaling pathway.
We found that absence of Ptpn22 increases BMDC secre-
tion of IL-1β in response to dectin-1 agonists, potentiating
IL-1β dependent IL-17 responses in vitro and in vivo. Recent stud-
ies have also suggested that Ptpn22 may regulate DC function
through IL-1β dependent mechanisms. For example, in a dex-
tran sulphate induced colitis model, Ptpn22−/− mice developed
severe colitis characterised by increased IL-1β derived from M1
macrophages [24]. A further association with IL-1β was made in
the K/BxN serum transfer arthritis model where poly(I:C) admin-
istration failed to protect against arthritis in either Ptpn22−/− or
Ptpn22R619W mice in part due to potentiated synovial IL-1β [8].
Another study reported that loss of Ptpn22 expression by shRNA
in THP-1 cells or Ptpn22−/− BMDCs reduced secretion of IL-1β in
response to pre-treatment with LPS followed by activation with
NLRP3 activators [13]; this is in contrast to our data where LPS
treatment alone did not alter IL-1β secretion (Supporting Infor-
mation Fig. 3C). Regardless of the specific context, the data point
to a conserved function of PTPN22 in regulating IL-1β expression
in myeloid cells. Our data provide an additional link between reg-
ulation of dectin-1 signaling by Ptpn22, IL-1β secretion and the
differentiation of T-cells to produce IL-17.
Pathways implicated in negative regulation of dectin-1 signal-
ing are much less well described than those that activate this
signaling cascade. To date several phosphatases have been associ-
ated with dectin-1 signaling. SHIP-1 is so far the only phosphatase
known to directly bind to the dectin-1 hemi-ITAM domain and
regulate ROS production [25]. In contrast, the membrane associ-
ated phosphatases CD45 and CD148 may regulate this pathway
and there is evidence that they are excluded from the dectin-
1 phagocytic synapse allowing receptor mediated phagocytosis
and anti-microbial responses [26]. Here, we report that Ptpn22
C© 2017 The Authors. European Journal of Immunology published by
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Figure 4. Curdlan stimulated Ptpn22−/− BMDCs induce enhanced IL-17 responses in an IL-1β dependent manner. WT and Ptpn22−/− derived bone
marrow derived dendritic cells (BMDCs) were pulsed overnight with OVA323-339 in the presence or absence of curdlan. BMDCs were harvested and
injected into the left footpad of OT-II mice in the presence or absence IL-1RA. 7 days post immunization the draining (left) popliteal lymph nodes
were isolated. Total draining lymph node T-cells were stimulated with immobilised anti-CD3 for 48 h and cell-free supernatants assayed for IL-17,
IFNγ and TNFα by immunoassay. Data are representative of two independent experiments with 3–5 mice per group per experiment, each point
representing an individual OT-II mouse lymph node. Data represent mean ± S.D. NS = not significant, *p < 0.05, **p < 0.01, ***p < 0.001 by two-way
ANOVA, applying Sidak’s multiple comparisons test.
deficiency results in enhanced activation of dectin-1 signaling
intermediates Syk and Erk. Whether Ptpn22 mediates negative
regulation through direct interactions with Syk or via indirect
effects on other kinases required for initiating Syk activation
remains to be determined. In T-cells, Ptpn22 associates directly
with the Syk family kinase ZAP-70, and loss of Ptpn22 leads to
enhanced Erk signaling [5, 27]. Erk activation following dectin-
1 engagement requires Syk, H-Ras, and Card-9 dependent sig-
nals, [22] inducing the secretion of IL-1β, IL-6 and TNFα. Our
studies also revealed that loss of Ptpn22 expression, or altered
function in the setting of the risk variant, conferred a selective
increase in dectin-1 induced IL-1β. The reasons for this specificity
are unclear. One explanation is that there may exist a require-
ment for distinct Erk signaling thresholds for the induction of
certain cytokine signatures [28]. We observed a subtle increase
in IL-1β transcription in Ptpn22−/− BMDCs compared to WT fol-
lowing curdlan stimulation (Supporting Information Fig. 7). IL-1β
processing can be induced by caspase 8 following Syk dependent
dectin-1 signaling, so it is conceivable that differences in activation
of caspase 8, which regulates IL-1β processing, could explain the
discrepancy between IL-1β protein andmRNA expression observed
between genotypes [29]. An alternate explanation therefore is that
Syk and Erk regulate IL-1β post-translational processing, as well as
transcriptional activity, through regulation of caspase 8 activity.
The prevalence of the Ptpn22R620W polymorphism in the
healthy population has led to the theory that it may confer a
protective or survival benefit against specific pathogens, such as
M. tuberculosis [12], a bacterium that induces dectin-1 dependent
IL-1β [30]. Although the association of Ptpn22 genetic variants
with autoimmune disease has been proposed to be due to its role
in lymphocyte signaling, environmental factors are also critical to
the initiation of autoimmune arthritis. Animal models of arthritis
clearly suggest that, besides curdlan, fungal phylotypes within the
intestinal microbiota are capable of triggering arthritic autoim-
munity [31, 32]. Additionally, Sakaguchi et al. demonstrated that
subclinical fungal infections drive inflammatory signals leading
Figure 5. Ptpn22 regulates dectin-1 dependent Syk and
Erk activation in BMDCs. (A–C)WT and Ptpn22−/− BMDCs
were stimulated with heat killed C. albicans (HKCA)
for the indicated time points. Whole cell lysates were
resolved by SDS-PAGE and immunoblotted using spe-
cific antibodies to pSyk (Tyr525/526) or Syk, and pErk1/2
(p42/44) or Erk. Quantification using ImageJ software
of HKCA induced band intensity measurements pooled
from five independent experiments are shown for pSyk
(B) and pErk (C), relative to Syk and Erk, respectively.
Phosphorylated Syk protein values were normalized to
total protein and the fold change to 0 min calculated.
Data are mean + S.E.M. from five independent exper-
iments with one sample per group per experiment.
*p < 0.05 applying two-way ANOVA, with Sidak’s multi-
ple comparisons test.
C© 2017 The Authors. European Journal of Immunology published by
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Figure 6. Ptpn22R619W regulates T cell dependent IL-17 responses induced by curdlan stimulated BMDCs in vivo. WT and Ptpn22R619W derived bone
marrow derived dendritic cells (BMDCs) were pulsed overnight with OVA323-339 in the presence or absence of curdlan. BMDCs were harvested and
injected into the left footpad of OT-II mice. Seven days post immunisation the non-draining and draining popliteal lymph nodes were isolated.
Total draining lymph node T-cells were stimulated with immobilised anti-CD3 for 48 h and cell-free supernatant assayed for (A) IL-17, IFNγ and
TNFα by immunoassay. Data are pooled from two independent experiments with 3–4 mice per group per experiment, each data point representing
an individual OT-II mouse lymph node. Bars represent the mean ± S.D. NS = not significant, **p < 0.01 by two-way ANOVA, applying Sidak’s
multiple comparisons test. (B) WT and Ptpn22R619W GM-CSF derived BMDCs were stimulated for 24 h in the presence or absence of curdlan.
Supernatants were assessed for secretion of IL-1β and IL-6 by immunoassay. Data shown are mean ± S.D. Data are pooled from 4 independent
experiments with one sample per group per experiment. NS = not significant, *p < 0.05, ***p < 0.001 by two-way ANOVA, applying Sidak’s multiple
comparisons test.
to spontaneous arthritis in SKG mice, which is also IL-1β and
IL-17 dependent [33, 34]. Recent evidence suggests that vimentin,
a cytoskeletal protein secreted by activated cells, is an endoge-
nous ligand of dectin-1 [35]. Serum autoantibodies against citrul-
linated vimentin, common in RA patients, have also been shown
to promote osteoclastogenesis and bone resorption in a mouse
model [36], raising the possibility that PTPN22 could regulate
vimentin-dectin-1 driven uptake and presentation of autoantigens,
in addition to cytokine secretion. Thus, genetic polymorphisms
perturbing DC pathogen sensing may contribute to autoimmunity
through a number of distinct mechanisms.
Materials and methods
Mice
Wild type (WT) C57BL/6, Ptpn22−/−, Ptpn22R619W mice, OT-II,
and OT-II x Ly5.2 were housed under specific pathogen free
(SPF) conditions and used in experiments according to UK
HomeOffice approved protocols. Ptpn22−/− mice and Ptpn22R619W
mutant mice were backcrossed for more than 12 generations to
the C57BL/6 strain and their generation, genotype and phenotype
has been previously described in detail [4, 37]. Age- and gender-
matched mice were used in the study.
Bone marrow derived dendritic cell (BMDC) culture
Bone marrow was flushed from femurs and tibias of
WT, Ptpn22−/− or Ptpn22R619W mice by using RPMI-1640
with L-glutamine (Corning) containing 1% FBS and peni-
cillin/streptomycin (100 μg/ml). Cells were seeded at 1.5 ×
106 cells/ml in 24-well tissue culture plates in RPMI-1640
with L-glutamine supplemented with 10% heat-inactivated FBS,
β-mercaptoethanol (50 μM), penicillin/streptomycin (100 μg/
mL), containing 1% murine GM-CSF. GM-CSF was produced from
the B78H1/GMCSF.1 cell line. BMDCs were cultured for 6 days at
37°C and 5% CO2 and medium replaced on days 3 and 4. At day
6 BMDCs were used in functional assays.
CD4+ T-cell isolation and BMDC co-culture
MACS negative selection kit (Miltenyi Biotech) was used to isolate
CD4+ T-cells from the lymph nodes (LN) and spleens of 8–16 week
old OT-II mice. T-cells (2 × 107 cells/mL) were labeled with 2 μM
CellTrace Violet (CTV) (Invitrogen) for 20 min at 37°C. BMDCs
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were pulsed overnight with OVA323-339 peptide (50nM Invivogen)
in the presence or absence of curdlan-AL (100 μg/mL Invivo-
gen). After washing, BMDCs were co-cultured with CTV labeled
CD4+ T-cells at 1:2 BMDC:T-cell ratio (1 × 105 BMDC:2 × 105
T-cells) in round bottomed 96-well plates. After 6 days cells were
washed, and replated in RPMI-1640 with L-glutamine supple-
mented with 10% heat-inactivated FBS, β-mercaptoethanol (50
μM), penicillin/streptomycin (100 μg/mL), the presence of IL-2
(1ng/mL Proleukin) and IL-23 (10 ng/mL R & D Systems) for 4
days.
Adoptive transfer
WT, Ptpn22−/−, or Ptpn22R619W BMDCs were incubated overnight
with 50nM OVA323-339 peptide in the presence or absence of
curdlan-AL (100 μg/mL). Cells were harvested and resuspended
in PBS prior to injecting 5 × 105 cells in 20 μL volume into the left
footpad of OT-II recipient mice. Where indicated, IL-1 receptor
antagonist (rhIL-1RA Biolegend) was added to BMDCs immedi-
ately before injection (0.5 μg/injection). After 7 days popliteal
LNs were isolated, and cell suspensions prepared. Total LN cells
were added to anti-CD3 (1 μg/mL clone; 17A2 Biolegend) coated
96-well plates. After 48 h cell-free supernatants were collected
and total LN cytokine secretion determined by immunoassay.
BMDC phenotype
Day 6 BMDCs were stimulated for 24 h in the presence or absence
of curdlan-AL (100 μg/mL). BMDCs were harvested and stained
for anti-mouse CD11c-PECy7 (clone; N418 Biolegend), MHCcII
I-Ab-FITC (clone; AF6-120.1 Biolegend), CD40-APC (clone; 3/23
Biolegend), and CD86-Brilliant Violet 650 (clone; GL-1 Biolegend)
and fixable viability dye eFluor-506 (eBioscience) in PBS contain
anti-mouse CD16/CD32 (Biolegend). Expression of maturation
markers was determined by gating on live, singlet, CD11c+ cells
and gates were set using fluorescence minus one controls. Cells
were fixed in FACS buffer (PBS, 5% FBS, 0.01% NaN3) contain-
ing 1% PFA and acquired using a Becton Dickinson Fortessa flow
cytometer and data analyzed using FlowJo Version 8.7.
Cytokine immunoassays and cell phenotyping
BMDC cultures were washed and replated at 1 × 106
cells/mL in RPMI-1640 with L-glutamine supplemented with
10% heat-inactivated FBS, β-mercaptoethanol (50 μM), peni-
cillin/streptomycin (100 μg/mL) and restimulated in the pres-
ence or absence of curdlan-AL (100 μg/mL), LPS (100 ng/mL
Invivogen) or heat-killed Candida albican cells (HKCA 6.25 ×
105c/mL strain ATCC 10231 Invivogen) for 24 h. Where indi-
cated anti-mouse dectin-1-IgG (10 μg/mL clone; R1-8g7 Invivo-
gen), Syk inhibitor II (2 μM Calbiochem), U0126 (10 μM Cell
Signaling Technologies) were added 30 min prior to stimula-
tion. Syk inhibitor II is a cell permeable pyrimidine-carboxamide,
which is a potent, selective, reversible and ATP-competitive
inhibitor of Syk [38]. U0126 is a highly selective inhibitor
of MEK1/2, which induce the activation of Erk [39]. IL-1β,
IL-6, IL-12/23p40, and TNFα cytokine concentrations were deter-
mined in cell-free supernatants by specific immunoassay. Co-
culture supernatants were harvested at the indicated times.
IL-17, IFNγ, and TNFα were determined by immunoassay.
Capture and detection (biotin-conjugated) antibody pairs were
purchased from Biolegend. Cytokine levels were determined
using DELFIA-streptavidin-europium and DELFIA-enhancement
solution (both Perkin Elmer) and detected on a Victor 1420
multilabel counter (Perkin Elmer). Day 10 BMDCs and OT-II
T-cell co-cultures were stimulated with PMA (10 ng/mL), ion-
omycin (500 ng/mL) and monensin (Biolegend) for 6 h. Cells
were stained with anti-CD3ε-FITC (clone; 145.2C11 Biolegend),
anti-CD4-PerCP (clone; RM4-5 Biolegend) and fixable viabil-
ity dye eFluor-506 (eBioscience). Cells were fixed and perme-
abilised (Foxp3 staining buffer set eBioscience), and incubated
with anti-IL-17-AlexaFluor-647 (clone; TC11-18H10.1 Biole-
gend), anti-IFNγ-PE (clone; XMG1.2 Biolegend) and anti-TNFα-
PECy7 (clone; MP6-XT22 Biolegend) at room temperature for
45 min, washed and resuspended in FACS buffer. Cytokine pro-
ducing T-cell populations were determined gating on live, singlet,
CD3+, CD4+ cells and cytokine quadrant gates were set using
monensin only controls. Cells were acquired using Becton Dickin-
son Fortessa or FACSCanto II flow cytometers and data analyzed
using FlowJo Version 8.7.
Heat killed Candida albicans uptake
Heat killed C.albicans (HKCA) (InvivoGen) were stained with
Zombie-Ultra Violet (UV) dead cell discrimination dye (Biole-
gend), and washed in PBS at 13 000 rpm for 5 min. BMDCs (2 ×
105 cells) were incubated with UV+ HKCA (2 × 106) on ice and
unbound HKCA was washed off with cold FACS buffer (PBS + 5%
FBS + 0.01% NaN3) and moved into the 37°C waterbath for time-
points up to 1 h. Subsequently cells were chilled on ice and BMDCs
were washed FACS buffer and stained with CD11c-PE/Cy7 (Biole-
gend) in PBS containing anti-CD16/CD32 and fixed with 1% PFA
and cells were acquired using a Becton Dickinson Fortessa flow
cytometer and data were analyzed using FlowJo software.
Immunoblotting
BMDCs were washed and resuspended at 6 × 106cells/mL
in RPMI-1640 with L-glutamine supplemented with β-
mercaptoethanol (50 μM), penicillin/streptomycin (100 μg/mL)
for 3 h prior to stimulation with HKCA (6.25 × 105cells/mL)
or curdlan (100 μg/mL) at 37°C for 0–20 min. Cells were lysed
(1% Triton, 120 mM NaCl, 50 mM Tris, 0.1% SDS, 1 mM EDTA,
containing protease/phosphatase inhibitors) and resolved in SDS-
PAGE gels and transferred to PVDF membranes, blocked (Tris,
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5% BSA, 0.05% Tween20) and probed with the indicated anti-
bodies; pSyk (clone; C87C1), Syk (clone; D1I5Q), pErk and Erk
(mAb Rabbit IgG), Pp38 (clone; D3F9), p38 (clone; D13E1), IκBα
(clone; 44D4), pIκBα (clone; 14D4) (all immunoblotting antibod-
ies from Cell Signaling Technologies) followed by anti-rabbit-HRP
(Dako) secondary antibody. Proteins visualized by SuperSignal
chemiluminescent reaction (Pierce) in a ChemiDoc station (Bio-
Rad). Densitometry measurements were performed with ImageJ
software.
Real-time PCR
Total RNA was extracted from BMDCs using TRIzol reagent,
and cDNA was reverse transcribed using first strand cDNA
synthesis using random hexamers. Gene expression was mea-
sured by TaqMan quantitative real-time PCR using FAM labeled
IL-1β (Mm00434228 m1Applied Biosystems) and VIC labeled 18S
probe. Gene expression was normalized to 18S housekeeper and
to unstimulated 0h control.
Statistical analysis
GraphPad Prism software was used for statistical analysis by one-
way ANOVA with Holm-Sidak’s post-test or two-way ANOVA with
Sidak’s post-test (paired or unpaired, two-tails).
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